Anya Biopharm Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	240.41	290.22	11.46	2.07
Short-Term Investments	146.14	163.93	-	-
Cash & Short-Term Investments	386.55	454.15	11.46	2.07
Cash Growth	-17.40%	3864.28%	454.50%	-
Accounts Receivable	0.12	3.4	0.17	0.56
Other Receivables	4.08	2.32	-	0.75
Receivables	4.2	5.72	0.17	1.31
Prepaid Expenses	1.64	-	-	1.46
Other Current Assets	0.72	2.01	1.41	0.76
Total Current Assets	393.11	461.88	13.03	5.6
Property, Plant & Equipment	9.03	9.15	1.72	2.5
Other Intangible Assets	5.99	5.08	5.08	0.6
Other Long-Term Assets	3.23	5.22	2.4	2.86
Total Assets	411.36	481.32	22.23	11.56
Accrued Expenses	8.89	6.47	1.85	1.38
Short-Term Debt	-	-	102.01	63.28
Current Portion of Leases	0.1	0.17	0.95	0.82
Current Unearned Revenue	-	3.23	-	-
Other Current Liabilities	1.02	1.24	0.61	0.36
Total Current Liabilities	10.01	11.11	105.41	65.84
Long-Term Leases	2.84	3.25	0.08	0.9
Total Liabilities	12.85	14.36	105.49	66.74
Common Stock	491.02	491.02	8.77	8.77
Additional Paid-In Capital	14.82	14.82	16.38	16.38
Retained Earnings	-107.13	-38.83	-108.39	-80.31
Comprehensive Income & Other	-0.22	-0.13	-0.04	-0.04
Total Common Equity	398.49	466.89	-83.28	-55.19
Minority Interest	0.02	0.08	0.01	0.02
Shareholders' Equity	398.5	466.97	-83.26	-55.18
Total Liabilities & Equity	411.36	481.32	22.23	11.56
Total Debt	2.94	3.41	103.03	65
Net Cash (Debt)	383.61	450.73	-91.58	-62.93
Net Cash Per Share	7.79	13.62	-40.16	-27.60
Filing Date Shares Outstanding	49.1	49.1	8.77	2.28
Total Common Shares Outstanding	49.1	49.1	8.77	2.28
Working Capital	383.09	450.77	-92.39	-60.24
Book Value Per Share	8.12	9.51	-9.50	-24.21
Tangible Book Value	392.5	461.8	-88.36	-55.79
Tangible Book Value Per Share	7.99	9.41	-10.07	-24.47
Machinery	3.96	2.69	1	0.94
Leasehold Improvements	3.38	3.8	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.